Fig. 7From: Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in ColombiaWillingness to pay curves to obtain the Maximum Net Benefit of palivizumab vs. placebo in infants with CHD in Colombia, 2022Back to article page